STOCKHOLM, October 29, 2012 /PRNewswire/ --
Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek Poszepczynski as Director of Business Development
Pharmalink AB, a Swedish specialty pharma company, today announces it has appointed Dr. Heather Cook as Director of Regulatory Affairs and Mr. Marek Poszepczynski as Director of Business Development.
Dr. Cook brings to Pharmalink over 15 years of experience within the pharmaceutical industry, with a proven track record in global regulatory affairs and clinical development. Prior to joining Pharmalink, Dr. Cook was Head of Department for Regulatory Development Projects at H. Lundbeck A/S. She was also Global Regulatory Affairs Director, Oncology for Astra Zeneca and held a number of other senior roles including Scientific Director for Neuroscience and Infection. She has worked in the UK, Canada, and Denmark and currently resides in Stockholm. Dr. Cook is also Partner, Pharma and Biotech R&D consultant at PharmaView Consulting HB. She has a PhD in Zoology from the University of Toronto and is completing an MBA at Stockholm School of Economics.
Marek Poszepczynski joins Pharmalink after a career spanning 10 years and combining financial and business development experience. Before joining Pharmalink, Mr. Poszepczynski was lead equity analyst at Handelsbanken covering European and Swedish biotechnology stocks. Prior to Handelsbanken, Mr. Poszepczynski was Vice President of Business Development at Karolinska Development, where he carried out a wide variety of tasks including streamlining the company's business operations as well as taking part in M&A, licensing and fund raising negotiations. Mr. Poszepczynski spent six years at BioVitrum AB where he was Director of Corporate Development, and part of the in-and-out licensing deals team of the company's R&D portfolio. Mr. Poszepczynski holds a Master of Industrial Engineering and Business Management from KTH Royal Institute of Technology, Stockholm.
Pharmalink's Managing Director Johan Häggblad said, "These appointments add significant talent and new experience to Pharmalink's management team as the Company continues to drive forward its late stage clinical development programs for Nefecon® and Busulipo™ and actively seeks new product opportunities. It is a measure of our reputation that such high caliber executives have joined us and I look forward to working with Heather and Marek through what is an exciting stage of development."
Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. With a successful history in pharmaceutical sales and marketing, and highly experienced, dynamic management team, Pharmalink is currently focused on the development of valuable, de-risked projects using a repurposing and reformulation strategy. It has two late-stage clinical phase products under development, Nefecon® and Busulipo™, having successfully divested its Xepol® product in 2010. Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications. Visit http://www.pharmalink.se for further information.
For further information, please contact:
Citigate Dewe Rogerson:
Chris Gardner/Nina Enegren, +44-207-638-9571
|SOURCE Pharmalink AB|
Copyright©2012 PR Newswire.
All rights reserved